fbpx
Home / 2018 / October

Monthly Archives: October 2018

Scientics and Biomarkers accurately distinguish mesothelioma from non-cancerous tissue

“The International Mesothelioma Interest Group (IMIG) recommends that a diagnostic marker of MPM have sensitivity/specificity of >0.80, and these criteria are fulfilled by our miRNA classifier,” comments Dr. Santoni-Rugiu. The authors suggest that diagnostic accuracy can be further improved by adding immunohistochemical testing of miRNA targets in biopsy tissue to …

Read More »

Lung-sparing surgery for patients with advanced mesothelioma results in prolonged survival, new study shows

Patients with advanced malignant pleural mesothelioma (MPM) treated with a combination of surgery to remove the cancer but save their lung, plus photodynamic therapy and chemotherapy, had a median survival of nearly three years, with a subset of patients living longer than seven years, according to new research published in …

Read More »

Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma

Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 “Malignant pleural mesothelioma …

Read More »

Discovery of four subtypes of melanoma points to new treatment approaches

Melanoma, a relatively rare but deadly skin cancer, has been shown to switch differentiation states — that is, to regress to an earlier stage of development — which can lead it to become resistant to treatment. Now, UCLA researchers have found that melanomas can be divided into four distinct subtypes …

Read More »

First immunotherapy for mesothelioma on the horizon, early research suggests

Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13-15 months. All patients relapse despite initial chemotherapy, more than 50% of them within six months after stopping …

Read More »

How melanoma tumors form

Melanoma cells move quickly, extending cables to reel in other cells and form tumors. The panels show how individual melanoma cells came together to build a tumor in just four hours.   There’s a reason why melanoma, the most serious type of skin cancer, is so aggressive. You just need …

Read More »

New therapeutic opportunity for the treatment of resistant malignant melanoma

New therapeutic opportunity for the treatment of resistant malignant melanoma A team of researchers led by Dr Pierre Close, WELBIO researcher at the ULiège GIGA Institute and Dr Francesca Rapino has uncovered a new therapeutic opportunity in the treatment of malignant melanoma that acquired resistance to targeted therapies. In collaboration …

Read More »

Study reveals how melanoma spreads

Cancerous tumors are voracious. Once they have consumed all the oxygen and nutrients in the original tumor site, the cancer cells travel to other parts of the body (metastasize) to find more nourishment. Searching for clues about how the body signals the lack of oxygen in melanoma skin cancer, National …

Read More »

Glycans at the ‘I’ of the storm in humoral immunity and melanoma progression

Two new studies have unveiled how a peculiar molecule impacts how antibody-producing cells develop and function as well as how normal melanocytes progress to melanoma malignancy. “These findings on fundamental immunology and melanoma development originate from totally different areas of research, though have intersected at the bench,” said Charles Dimitroff, …

Read More »

Lung-sparing surgery for patients with advanced mesothelioma results in prolonged survival, new study shows

Patients with advanced malignant pleural mesothelioma (MPM) treated with a combination of surgery to remove the cancer but save their lung, plus photodynamic therapy and chemotherapy, had a median survival of nearly three years, with a subset of patients living longer than seven years, according to new research published in …

Read More »
Change Language »